Welcome to our dedicated page for Quince news (Ticker: QNCX), a resource for investors and traders seeking the latest updates and insights on Quince stock.
Quince Therapeutics Inc (QNCX) is a preclinical-stage biopharmaceutical company pioneering bone-targeted therapies for rare diseases and fractures. This page aggregates official news and press releases to help stakeholders track scientific advancements, strategic partnerships, and regulatory developments.
Key Resources: Access timely updates on clinical research milestones, financial disclosures, and leadership announcements. Our curated collection ensures investors and researchers stay informed about QNCX's innovative drug delivery platform and its potential market impact.
Content Includes: Earnings reports, preclinical trial updates, intellectual property filings, and collaborations within the regenerative medicine sector. All materials are sourced directly from company communications to ensure accuracy.
Bookmark this page for streamlined access to Quince Therapeutics' latest developments. Check regularly for updates on their bone-targeting platform and progress toward addressing unmet medical needs.
Quince Therapeutics (NASDAQ: QNCX) has received a Notice of Allowance from the USPTO for a patent application covering their method of treating Ataxia-Telangiectasia (A-T) using the EryDex process. The patent, extending to 2036, covers the preparation of erythrocytes loaded with pharmaceutical substances.
The new patent application supplements existing U.S. Patent No. 10,849,858 and features broader claims than the parent patent. Once issued, the patent will be listable in the FDA's Orange Book, requiring generic applicants to certify against Quince's patent, providing notice of future generic applications and stay provisions under the Hatch-Waxman Act.
This protection complements the market exclusivity provided by Orphan Drug Designation in both the U.S. and Europe. The company plans to pursue similar claims with the European Patent Office.
Quince Therapeutics (Nasdaq: QNCX) has announced an upcoming investor webinar focused on Ataxia-Telangiectasia (A-T), scheduled for February 7, 2025, at 10:00 a.m. Eastern Time. The webinar will feature Dr. Mary Kay Koenig, a leading A-T expert and board-certified child neurologist, who will present on A-T natural history, current treatments, competitive landscape, and Quince's Phase 3 EryDex clinical trial.
Dr. Dirk Thye, Quince's CEO and CMO, will provide a corporate overview and update on the ongoing Phase 3 NEAT clinical trial enrollment. Dr. Koenig, currently serving as Professor and Associate Vice-Chair for Clinical Research at McGovern Medical School, brings extensive expertise in neurodegenerative disorders and holds multiple leadership positions, including Director at the Center for Treatment of Pediatric Neurodegenerative Disease.
Quince Therapeutics (NASDAQ: QNCX) announced the publication of safety data in Frontiers in Neurology regarding EryDex treatment in pediatric patients with Ataxia-Telangiectasia (A-T). The data comes from patients treated for a minimum of 24 months in Phase 3 clinical trials.
EryDex, which encapsulates dexamethasone sodium phosphate in patients' own red blood cells, demonstrated favorable safety profiles without the typical chronic side effects associated with standard corticosteroid treatment. The company has administered over 6,000 monthly doses to nearly 400 patients over 10+ years.
The most common treatment-related side effect was temporary infusion-related pruritus. The company is currently conducting the pivotal Phase 3 NEAT trial under a Special Protocol Assessment agreement with the FDA, with topline results expected in Q4 2025. Quince plans to submit New Drug Application to FDA and Marketing Authorization Application to EMA in 2026, pending positive results.
Quince Therapeutics (Nasdaq: QNCX) has appointed Dr. William Whitehouse to its Scientific Advisory Board (SAB). Dr. Whitehouse, an Honorary Clinical Associate Professor at the University of Nottingham and retired Consultant Paediatric Neurologist at Nottingham Children's Hospital, brings extensive expertise in rare pediatric neurodegenerative diseases, particularly Ataxia-Telangiectasia (A-T). He joins seven founding SAB members who are experts in various medical fields.
Dr. Mauro Magnani, Chair of Quince's SAB, highlighted Dr. Whitehouse's valuable contributions to advancing Quince's lead asset, EryDex, aimed at treating A-T. Dr. Whitehouse expressed enthusiasm for collaborating with Quince's team to support EryDex's development, which has the potential to be a first-to-market treatment for A-T.
Dr. Whitehouse has a distinguished academic and clinical background, with significant contributions to A-T research and care. His appointment is expected to bolster Quince's efforts in treating rare diseases, with a pivotal Phase 3 clinical trial for EryDex currently underway. Quince's SAB will also aid in expanding the company's pipeline to include other rare disease indications.
Quince Therapeutics (QNCX) reports progress in its Phase 3 NEAT clinical trial for Ataxia-Telangiectasia treatment, with 32 patients enrolled across U.S., U.K., and EU sites. The company aims to complete enrollment in Q2 2025 and report topline results in Q4 2025. Financial highlights include $47.8 million in cash and equivalents, R&D expenses of $4.9 million, and a net loss of $5.5 million ($0.13 per share) for Q3 2024. The company expects its cash runway to fund operations through Phase 3 NEAT results and into 2026, including $20 million for the NEAT trial and $15 million for an open-label extension study.
Quince Therapeutics (Nasdaq: QNCX) presented data from its Phase 3 ATTeST clinical trial at the 2024 International Congress for Ataxia Research. The trial evaluated EryDex for treating Ataxia-Telangiectasia (A-T). Key findings showed that 24-month EryDex treatment didn't adversely affect growth and bone mineral density in A-T patients, comparing favorably to natural disease progression. The study also identified that mICARS and RmICARS measures best reflect disease progression in A-T patients aged 6-10 years. Quince is currently conducting a pivotal Phase 3 NEAT trial under FDA Special Protocol Assessment, with topline results expected in Q4 2025.
Quince Therapeutics (Nasdaq: QNCX) presented safety data from its Phase 3 ATTeST clinical trial at the 53rd Child Neurology Society Annual Meeting. The trial evaluated EryDex (intra-erythrocyte dexamethasone sodium phosphate) in Ataxia-Telangiectasia (A-T) patients. Results showed EryDex was generally well-tolerated with mostly mild to moderate side effects. The company is currently conducting a pivotal Phase 3 NEAT trial, expecting to enroll 86 patients aged 6-9 years and 20 patients aged 10+ years. Topline results are expected in Q4 2025, with potential FDA and EMA submissions in 2026.
Quince Therapeutics (Nasdaq: QNCX), a late-stage biotechnology company focusing on rare diseases, has announced its participation in three upcoming investor conferences:
1. 2024 Maxim Healthcare Virtual Summit: CEO and CMO Dirk Thye, M.D., will participate in a fireside chat on October 17, 2024, at 3:00 p.m. ET.
2. LD Micro Main Event XVII: COO and CBO Brendan Hannah will present a company overview on October 29, 2024, at 6:30 p.m. ET.
3. ThinkEquity Conference 2024: President Charles Ryan, J.D., Ph.D., will present a company overview on October 30, 2024, at 3:00 p.m. ET.
Webcasts and registration details for these events are available on Quince's Investor Relations website.
Quince Therapeutics (Nasdaq: QNCX), a late-stage biotech company focusing on rare diseases, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Dr. Dirk Thye, the company's CEO and CMO, will present on September 9, 2024, at 7 a.m. Eastern Time.
This presentation marks an important opportunity for Quince to showcase its progress and potential to investors. The company's approach centers on harnessing a patient's own biology for treating rare diseases, a cutting-edge area in biotechnology. Interested parties can access a webcast of the presentation through Quince's Investor Relations website, providing transparency and accessibility to potential investors and stakeholders.
Quince Therapeutics (Nasdaq: QNCX) announced the publication of Phase 3 ATTeST clinical trial data in The Lancet Neurology, evaluating EryDex for treating Ataxia-Telangiectasia (A-T). The study, involving 175 participants across 22 institutions in 12 countries, demonstrated a favorable safety profile and positive effects in patients aged 6-9 years.
Key findings include:
- No serious safety concerns typically associated with chronic corticosteroid use
- Statistically significant reduction in neurological symptoms in 6-9 year olds receiving high-dose EryDex
- Potential treatment delays due to COVID-19 pandemic affected overall results
Quince has initiated the pivotal Phase 3 NEAT study under FDA Special Protocol Assessment, with topline results expected in Q4 2025.
FAQ
What is the current stock price of Quince (QNCX)?
What is the market cap of Quince (QNCX)?
